Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 9 Months Ended 110 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Consolidated Statements Of Operations          
Revenues               
Total revenues               
Operating expenses:          
Amortization & depreciation 194 152 582 303 76,931
General and administrative 117,832 138,199 500,370 2,315,046 13,068,319
Total operating expenses 118,026 138,351 500,952 2,315,349 13,145,250
Gain (loss) from operations (118,026) (138,351) (500,952) (2,315,349) (13,145,250)
Other income (expense):          
Gain/(Loss) on fair value adjustment - derivatives 318,799    (70,498)    (518,635)
Stock option expense (40,377)    (121,330)    (121,330)
Gain on debt reversal 81,307    86,878    86,878
Gain on sale of fixed asset          4,790 4,790
Interest expense (25,014) (20,704) (91,071) (69,384) (1,184,063)
Interest expense - beneficial conversion feature (19,501) (38,217) (152,993) (102,388) (335,057)
Total other income (expense) 315,214 (58,921) (349,014) (166,982) (2,067,417)
Income (loss) before provision for income taxes 197,188 (197,272) (849,966) (2,482,331) (15,212,667)
Provision for income tax               
Net income (loss) 197,188 (197,272) (849,966) (2,482,331) (15,212,667)
Less: Net (income) loss attributable to noncontrolling interest 618 2,686 5,803 7,860 94,260
Net income (loss) attributable to TransBiotec, Inc. $ 197,806 $ (194,586) $ (844,163) $ (2,474,471) $ (15,206,864)
Net income (loss) per share (TransBiotec, Inc.)          
(Basic and fully diluted) $ 0.01 $ (0.01) $ (0.03) $ (0.09)  
Weighted average number of common shares outstanding 33,431,576 28,250,526 32,005,187 27,384,853